Rohto Pharmaceutical Co ( (RPHCF) ) has released its Q2 earnings. Here is a breakdown of the information Rohto Pharmaceutical Co presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Rohto Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical sector, primarily engaged in the development, manufacturing, and sale of health and wellness products, including skincare and over-the-counter medicines, with a strong presence in both domestic and international markets.
In its latest earnings report for the six months ended September 30, 2025, Rohto Pharmaceutical Co. showcased impressive financial performance, marked by significant increases in net sales and profits. The company reported a notable year-on-year growth in net sales by 18.1% to 164,257 million yen and a substantial rise in profit attributable to owners of the parent by 36.6% to 17,652 million yen.
Key financial highlights include a 32.4% increase in ordinary income to 24,609 million yen, driven by a decrease in research and development expenses and an increase in dividend income. The company’s strategic expansion in Asia, particularly through the acquisition of Eu Yan Sang International Ltd., contributed to a 51.3% increase in sales in the region. Additionally, the inclusion of Mono chem-pharm Produkte GmbH in Europe bolstered sales, despite some challenges in production costs.
Rohto’s financial position remains robust, with total assets increasing to 439,904 million yen and net assets rising to 292,268 million yen. The company has also revised its full-year forecast upwards, expecting net sales to reach 338,500 million yen, reflecting confidence in continued growth across its segments.
Looking ahead, Rohto Pharmaceutical Co. remains focused on its long-term growth strategy, aiming to enhance its market presence and product offerings globally. The management’s outlook is optimistic, supported by strategic acquisitions and product innovations, positioning the company well for future success in the competitive pharmaceutical industry.